Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Singer

Showing results (181-190 of 313) with videos related to

Pageof 32
Sort By:
Circulation. Arrhythmia and Electrophysiology|June 25, 2025
Wearable Irregular Heart Rhythm Detection Recurrences and Electrocardiographic Atrial Fibrillation Confirmation: The Fitbit Heart StudySteven A Lubitz, Michael V McConnell, Caitlin Selvaggi, et al.
Journal of the American Heart Association|September 3, 2021
Comparative Clinical Effectiveness of Population-Based Atrial Fibrillation Screening Using Contemporary Modalities: A Decision-Analytic ModelShaan Khurshid, Wanyi Chen, Daniel E Singer, et al.
Heart Rhythm O2|June 11, 2025
Clinical and socioeconomic factors associated with recurrent atrial fibrillation after catheter ablation or antiarrhythmic drug therapyJaejin An, Nisha Bansal, Chengyi Zheng, et al.
Circulation. Cardiovascular Quality and Outcomes|May 13, 2017
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Ryan Orgel, Daniel Wojdyla, David Huberman, et al.
Journal of Substance Abuse Treatment|October 30, 2021
Understanding engagement behaviors and rapport building in tobacco cessation telephone counseling: An analysis of audio-recorded counseling callsKristina Schnitzer, Nicole Senft, Hilary A Tindle, et al.
Circulation. Cardiovascular Quality and Outcomes|March 25, 2024
Estimating Vitamin K Antagonist Anticoagulation Benefit in People With Atrial Fibrillation Accounting for Competing Risks: Evidence From 12 Randomized TrialsSachin J Shah, Carl van Walraven, Sun Young Jeon, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|May 20, 2023
Can Treatment Support Mitigate Nicotine Metabolism-Based Disparities in Smoking Abstinence? Secondary Analysis of the Helping HAND 4 TrialScott S Lee, Yuchiao Chang, Nancy A Rigotti, et al.
Circulation|March 2, 2022
Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: VITAL-AF Randomized Controlled TrialSteven A Lubitz, Steven J Atlas, Jeffrey M Ashburner, et al.
American Heart Journal|July 22, 2019
Design and rationale of a pragmatic trial integrating routine screening for atrial fibrillation at primary care visits: The VITAL-AF trialJeffrey M Ashburner, Steven J Atlas, David D McManus, et al.
Journal of Cardiology|March 6, 2016
Factors influencing left atrial volume in a population with preserved ejection fraction: Left ventricular diastolic dysfunction or clinical factors?Seitetsu L Lee, Masao Daimon, Tomoko Nakao, et al.
Pageof 32

Showing results (181-190 of 313) with videos related to

Sort By:
Pageof 32
Circulation. Arrhythmia and Electrophysiology|June 25, 2025
Wearable Irregular Heart Rhythm Detection Recurrences and Electrocardiographic Atrial Fibrillation Confirmation: The Fitbit Heart StudySteven A Lubitz, Michael V McConnell, Caitlin Selvaggi, et al.
Journal of the American Heart Association|September 3, 2021
Comparative Clinical Effectiveness of Population-Based Atrial Fibrillation Screening Using Contemporary Modalities: A Decision-Analytic ModelShaan Khurshid, Wanyi Chen, Daniel E Singer, et al.
Heart Rhythm O2|June 11, 2025
Clinical and socioeconomic factors associated with recurrent atrial fibrillation after catheter ablation or antiarrhythmic drug therapyJaejin An, Nisha Bansal, Chengyi Zheng, et al.
Circulation. Cardiovascular Quality and Outcomes|May 13, 2017
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Ryan Orgel, Daniel Wojdyla, David Huberman, et al.
Journal of Substance Abuse Treatment|October 30, 2021
Understanding engagement behaviors and rapport building in tobacco cessation telephone counseling: An analysis of audio-recorded counseling callsKristina Schnitzer, Nicole Senft, Hilary A Tindle, et al.
Circulation. Cardiovascular Quality and Outcomes|March 25, 2024
Estimating Vitamin K Antagonist Anticoagulation Benefit in People With Atrial Fibrillation Accounting for Competing Risks: Evidence From 12 Randomized TrialsSachin J Shah, Carl van Walraven, Sun Young Jeon, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|May 20, 2023
Can Treatment Support Mitigate Nicotine Metabolism-Based Disparities in Smoking Abstinence? Secondary Analysis of the Helping HAND 4 TrialScott S Lee, Yuchiao Chang, Nancy A Rigotti, et al.
Circulation|March 2, 2022
Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: VITAL-AF Randomized Controlled TrialSteven A Lubitz, Steven J Atlas, Jeffrey M Ashburner, et al.
American Heart Journal|July 22, 2019
Design and rationale of a pragmatic trial integrating routine screening for atrial fibrillation at primary care visits: The VITAL-AF trialJeffrey M Ashburner, Steven J Atlas, David D McManus, et al.
Journal of Cardiology|March 6, 2016
Factors influencing left atrial volume in a population with preserved ejection fraction: Left ventricular diastolic dysfunction or clinical factors?Seitetsu L Lee, Masao Daimon, Tomoko Nakao, et al.
Pageof 32